

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

20 March 2006

Dear Sir,

Resonance Health Granted Second US Patent

Resonance Health (ASX: RHT) has received formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application (10/820727) entitled: "Method of estimating the spatial variation of magnetic resonance imaging radiofrequency (RF) signal intensities within and object from the measured intensities in a uniform intensity medium surrounding the object." This patent covers a novel method of obtaining increased signal intensity from magnetic resonance images (MRI) without losing quantitative spatial information, a task that is important in the field of non-invasive tissue iron measurement.


This patent is an extension of the core intellectual property relating to Resonance Health's novel Magnetic Resonance Imaging (MRI)-based method for accurately measuring iron concentrations in the body, which already has patents in the US and Europe. The patent, with priority date of 9th April 2003, is currently being prosecuted in other jurisdictions.

The company has also recently filed a new patent application describing a novel non-invasive measure of liver structure that has application in the non-invasive measurement of fibrosis of the liver.

The granting of this second US patent provides further evidence as to the breadth and substance of Resonance Health intellectual property position and its leadership position in the area quantitative applications of MRI in the diagnosis of human disease.

About Resonance Health Ltd

Resonance Health (ASX: RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI)-related technology for the quantitative measurement of iron levels in the human body. Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering



significant added value for our MRI customers who deliver our service through their networks.

In 2005, RHT began the global commercial launch of FerriScan®, its world-leading non-invasive tool for measuring liver iron levels.

The FerriScan service involves an MRI scan followed by off-site processing of the images by RHT using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHT analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level. FerriScan provide a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders such as hereditary haemochromatosis and thalassemia. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in the US, Australia, UK and Europe. Further information about Resonance Health and FerriScan can be obtained from the following websites: www.resonancehealth.com and www.ferriscan.com.

Media and investor relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M - +61 422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director Resonance Health Limited T - +61 8 9286 5300 M - +61 409 050 519 Email: jamesw@ferriscan.com